Sperm, hybrid micromotor, tumor targeting, drug delivery, gynecologic cancers, in situ mechanical release ABSTRACT A sperm-driven micromotor is presented as cargo-delivery system for the treatment of gynecological cancers. This particular hybrid micromotor is appealing to treat diseases in the female reproductive tract, the physiological environment that sperm cells are naturally adapted to swim in. Here, the single sperm cell serves as an active drug carrier and as driving force, taking advantage of its swimming capability, while a laser-printed microstructure coated with a 2 nanometric layer of iron is used to guide and release the sperm in the desired area by an external magnet and structurally imposed mechanical actuation, respectively. The printed tubular microstructure features four arms which release the drug-loaded sperm cell in situ when they bend upon pushing against a tumor spheroid, resulting in the drug delivery, which occurs when the sperm squeezes through the cancer cells and fuses with cell membrane. Sperms also offer higher drug encapsulation capability and carrying stability compared to other nano and microcarriers, minimizing toxic effects and unwanted drug accumulation. Moreover, sperms neither express pathogenic proteins nor proliferate to form undesirable colonies, unlike other cells or microorganisms do, making this bio-hybrid system a unique and biocompatible cargo delivery platform for various biomedical applications, especially in gynecological healthcare.
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INTRODUCTION
The development of drug delivery systems that provide effective doses locally in a controlled way is one of the main challenges in the worldwide fight against cancer. 1, 2 Among such nano-and microcariers, liposomes were shown to be able to lower the cytotoxicity, improve the solubility and control the release of drugs. 3 Despite surface functionalization that allows them to increase the circulation time 4 and active tumor targeting ability, 5 there are still a lot of challenges to address, such as unspecific uptake by other organs, 6 limited tissue penetration 7 and the decrease of effective concentration due to the dilution in body fluids. 8 To overcome the abovementioned challenges, novel cellular carriers have been proposed, that take advantage of the membrane fluidity, long lifespan and high biocompatibility of cells. 9 As examples, stem cells as a combinatorial drug delivery system have been used for regenerative therapy, 10 macrophages for anticancer drug delivery 11 and red blood cells for sustained drug release in blood. 12 However, a precise transport method is particularly necessary for targeted drug delivery. Self-propelled cells, which provide a combination of cellular encapsulation and propulsion, are attractive due to their biocompatibility, ability to interact with other cells/tissue and optimal swimming performance in physiological microenvironments. 13, 14 Bacteria, for example, have been reported as promising self-propelled carriers. 15 Combined with their chemotactic, 16 and/or magnetotactic properties 17 or associated guidance components, 18 bacteria can transport and deliver drugs or perform in situ sensing. It is however noteworthy that rapid clearance or even autoimmune reactions might be caused by the immune response to certain bacteria. 19 In this work, we report a new type of sperm-hybrid micromotor and its potential application in targeted drug delivery to treat gynecologic cancers, including cervical, ovarian, uterine, vaginal, vulvar and fallopian tube cancers, which are affecting more than 100.000 women every year in the United States. 20 The here reported micromotor comprises a motile sperm that serves as the propulsion source and drug carrier, and a 3D printed four-armed microtube, also called "tetrapod", used for the magnetic guidance and mechanical release ( Figure 1a ). Compared to other drug carriers, sperms are naturally optimized to swim efficiently through the female reproductive system and can load a high amount of drugs, 21 making them good candidates as drug carriers toward gynecologic cancer treatment. The sperm cell provides an extraordinary ability to encapsulate protein and other hydrophilic drugs owing to its crystalline nucleus. 22 The sperm membrane can protect drugs from body fluid dilution, immune-reactions and the degradation by enzymes. Sperms, with their compact membrane system, can efficiently avoid dose dumping, which is regarded as a major issue of micelles. 23 For microscale carriers such as microspheres, micro capsules, and drug-loaded micromotors, 24, 25 drug uptake is always a problematic issue. 26 Sperm cells, with their somatic cell-fusion ability, 27 are expected to improve the drug transfer to the target cells and the drug availability as well. Several proteins from the sperm membrane, such as CD9 and integrins are involved in this process. 27 It solves the uptake problem of microscale carriers via the nanoscale mechanism of membrane fusion. Providing controllable guiding and release mechanisms, sperm-hybrid micromotors can potentially deliver drugs precisely to tumor tissue and furthermore avoid undesired drug accumulation in healthy tissue. The concept of a hybrid microdevice consisting of a sperm cell and a synthetic component was introduced in our previous research, where micromotors have been successfully employed to transport and guide single sperm cells as a promising approach for in vivo assisted fertilization. 13, 28 In the here presented work, we pursue a different application, however staying in the field of gynecologic medicine to take advantage of the sperms' natural adaptability to the reproductive system. This novel system combines several intriguing features, namely self-propulsion, in situ mechanical release of the drug-loaded sperm, penetration ability and high drug loading capacity. Besides, sperm-hybrid micromotors are exceptionally well-suited to swim through the female reproductive tract due to the naturally developed specialization of the cellular component.
RESULTS

Guidance and sperm release
The tetrapod microstructure was designed to have a tubular body and four flexible arched arms ( Figure 1a ). These arms protrude from one opening of the microtube in a curved manner. The dimensions of the microstructure are shown in Figure 1b ,c. At the narrowest point between the four arms, the maximum distance is 4.3 µm. In preliminary experiments, the dimensions of the structure were optimized according to the dimensions of a sperm cell (for the experiments shown in this manuscript, bovine sperm cells were selected for their similar paddle-like shape to human sperms), of which the head is on average 4.5 µm wide, 1 µm thick and 10 µm long. 29, 30 Therefore, the sperm can be captured to propel the microstructure. Once the arms hit a substantial barrier, such as a cell cluster, they bend to enlarge the distance between the arms allowing the sperm to escape from the tube in the process (Figure 1a ). The polymeric structure was designed and fabricated by means of two-photon 3D nanolithography (Figure 1c ). Then the tetrapod microstructure was asymmetrically coated with 10 nm of iron with a tilt angle of 15º to create a magnetic "easy axis". An additional layer of 2 nm of titanium was deposited to improve the composite's biocompatibility. A simulation was performed with finite element software to validate the optimum tetrapod geometry (detailed parameters shown in SI). This simulation indicated that the applied force of 128 pN by a motile sperm 31 results in the arms deformation, increasing the aperture or diagonal distance between them in about 328 nm (Figure 1d ). Such deformation is enough for the sperm to be released. The enlargement would be increased up to 1018 nm when the applied force is 450 pN which could be generated by a hyperactivated sperm. 32 To ensure the sperm release from the microstructure, progesterone was added to the sperm medium to hyperactivate sperms. 33 Video S1 demonstrates the elasticity and shape memory of the arms by repeatedly pressing down the arm with an AFM tip towards the substrate. The arms were bent but returned to their original position without damage. When an approaching sperm reaches the microstructure, it gets mechanically trapped inside the cavity of the tubular part and start to push the tetrapod forward (Video S2). The tubular body of the tetrapod is only 2 µm longer than the sperm head, thus the sperm tail can still beat freely outside the tube to provide powerful propulsion as it was previously demonstrated by our group. 34 Compared to free sperms, the average swimming velocity of the sperm-hybrid micromotors is nonetheless decreased by 43% from 73 ± 16 µm/s to 41 ± 10 µm/s (for 15 samples of sperm-hybrid micromotors). The main reason for the velocity reduction is thought to be the increase of the fluid drag that is provoked by the synthetic material and the complex structure of the tetrapod. It was reported that the swimming velocity of sperms is influenced by temperature and the rheology of the medium as well. 35 The asymmetrically distributed metal coating makes it possible to guide a tetrapod microstructure or a sperm-hybrid micromotor and even manipulate several of them simultaneously (Video S3). Figure 2a illustrates a rectangular track of a guided sperm hybridmicromotor, also shown in Video S3. The hybrid motor was easily steered by changing the direction of the external magnet. In most cases, the hybrid micromotor rotates while it moves forward due to the helical motion of the sperm, 36 which means the tetrapod does not change the characteristic motion of the sperm. Figure 2b illustrates vertical guidance of a sperm-tetrapod. The hybrid micromotor was steered to swim vertically out of plane simply when the external magnet was placed vertically. Thereby the swimming depth of the tetrapod could be adjusted. Pluronic® F-127 solution was reported previously as sperm repellent agent. 37 Prior to the experiments with sperm cells, tetrapods were thus treated with Pluronic® F-127 solution to reduce undesired adhesion between the sperm membrane and the tetrapod surface. Video S4a shows the motion of the sperm-tetrapod without adhesion in which the sperm cell rotates inside the tetrapod. In the nonadhesion situation, sperms immediately swam out when the tetrapod arms hit an obstacle.
However, the majority of tetrapods was found to rotate together with captured sperms due to either surface interaction between the sperm membrane and the material surface or the mechanical locking of the sperm head inside the structure (Figure 2c ). In these cases, it always took several seconds from the moment the tetrapod hit a wall until complete release of the contained sperm (Video S4b,c).
PDMS microfluidic channels were fabricated as a platform for the investigation of the sperm release mechanics. Sperm release occurred when two arms hit a corner (Video S4a,b) or when four arms hit a wall (Video S4c), while the release processes are different in both cases. When the motors came into contact with the targeted barriers, they still rotated for a while after the forward swimming was stopped. The rotating sperm-tetrapod stopped faster when two arms hit a corner because of the geometric gap between the arms which was easily caught on a corner. Once the rotation stopped, the sperm cell escaped when the tetrapod arms opened (release in 7 s). When four arms hit a wall, the rotation was not stopped because the arms were not locked. Thus, the sperm release took longer when four arms were bent on a wall (12 s). In both cases, tetrapods were pushed back by around 3 µm after the sperms escaped. The reason for these recoils is the existence of an elastic force that makes the tetrapod arms recover their original shape once the pushing sperm is gone. Even though there is a substantial diversity in bovine sperm dimensions, swimming behaviors and fabricated tetrapods within a sample, more than 2/3 (15 out of 22) of the coupled motors were shown to successfully release sperm cells. Previous research has reported similar elastic structures on the microscale that were also fabricated by two-photon lithography. 38 For example, a microscale beam was deformed by around 5 µm under compression with 68 pN. 39 The elasticity of such photosensitive polymeric material depends on the type of monomer and the cross-linking parameters. 38 In order to avoid uncontrolled release events, we did not choose a softer polymer material but optimized the laser power that initializes cross-linking (5 mW). In our simulation, the applied force was given according to the maximum pushing force of a sperm in low-viscosity fluid (2.29 × 10 -3 Pa·s). 31 It has been reported that the sperm can generate a more powerful force when the head is pushing against an obstacle.
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Furthermore, the force can be up to 20 times higher when the sperm is hyperactivated and swims in the viscoelastic fluid of the female reproductive system. 32 Consequently, we believe that sperms can be released with such a mechanical trigger system also, and maybe even more efficiently, under physiological conditions.
Drug loading of sperm
We used DOX-HCl as a model drug to evaluate the encapsulating performance of sperms.
Doxorubicin (DOX) has been approved as a chemotherapy medication with a broad application spectrum in cancer therapy since 1974. 41 Its liposomal form (Doxil) is also used primarily for gynecological cancer treatment. 42 Hence, the loading ratio remains at around 15 % for all concentrations. For the maximum concentration of DOX-HCl in our experiments, the loading amount was up to 37 µg/mL in 500 µL sperm solution. This amount indicates an average encapsulation of 15 pg of DOX-HCl per single sperm cell. We also carried out a test on the encapsulating stability. The result shows that only 18 % of drug was leaked into the solvent after 96 h ( Figure S2 ). This means that the DOX-HCl encapsulation by sperm is sufficiently stable for subsequent drug delivery experiments.
The sperm membrane consists of a lipid bilayer with embedded proteins. Sperms are expected to encapsulate most of the hydrophobic drugs into the cytoplasm and the nucleus. 43 After maturation, reduced cytoplasm remains in the midpiece and the head of a healthy sperm. 44 In addition, the condensed chromosomes can absorb a specific amount of hydrophilic substance by binding to proteasomes. 45 After a certain time of co-incubation with sperms, most of the DOX-HCl and BSA (Bovine Serum Albumin, used as a model for protein drugs) was found in the sperm head and the midpiece ( Figure 3b and Figure S3 ). In contrast, BSA was also retained in the sperm tail, which is the result of the protein absorbability of the cell membrane. DOX-HCl attacks cancer cells by interfering with the macromolecular biosynthesis. 46 Unlike cancer cells, mature sperms have terminated most of their macromolecular synthesis due to the lack of the complete endomembrane system, which avoids the digestion of the drug inside the sperm cell. 47 What is more, it is not necessary for sperm cells to express new proteins to maintain their motility. The propelling power is generated in the mitochondria in the midpiece. 44 Since DOX-HCl also interferes with the macromolecular synthesis in mitochondria, 48 it may also inhibit the energy metabolism of sperms, which is probably the reason for the observed decrease of the sperm's average swimming velocity from 71 µm/s to 57 µm/s, which is, however, still an acceptable velocity to serve the sperms'
purpose. The result of the drug loading ratio calculation highlights the high encapsulation capacity of sperm cells. Previous research showed successful loading of DOX into macrophages. 49 It was demonstrated that a more concentrated dose of DOX was found inside the cell (2.5 pg per cell), particularly in the nucleus, compared to the DOX solution that was co-incubated with the macrophages (cell size roughly 15-20 µm). We observed a similar phenomenon during the drug loading into sperm cells, as depicted in Figure 3 . ATP-mediated permeabilization of the cell membrane was regarded as an explanation for this loading profile. Sperm cells exhibit improved uptake of ionic DOX-HCl 50 compared to molecular DOX, which is normally taken in by facilitated diffusion. 41 Further research is required to investigate the transport mechanism through the sperm's cell membrane. We believe that this approach of using living cells could lead to a new dosage strategy that allows high local doses of anticancer agents while reducing systemic toxic effects.
Another advantage of the sperms comes from their incomplete metabolic system. 44 A Sperm cell can protect a contained drug within its lipid bilayer like a liposome, but does not metabolize the drug like stem cells or other somatic cells would do. Because of our observation that the swimming velocity significantly decreased when the DOX-HCl concentration was higher than 100 µg/ml, a concentration of 100 µg/mL was used to prepare DOX-HCl-loaded sperms in the subsequent experiments. hours. Figure 5c shows the membrane fusion of a sperm head and a HeLa cell in 24 hours after sperm release, the anterior part of the sperm head was not visible anymore while the posterior part of the sperm head and the flagellum could still be distinguished. Previous research explained this interaction with the somatic fusion ability of acrosome-reacted spermatozoa. 27 Taking advantage of the cell fusion ability of sperms, our sperm-hybrid system shows a practical potential to enhance the drug uptake and availability by transporting it from cell to cell (sperm to HeLa cell) without dilution into the extracellular medium. the drug solution with the same dose. Sperms also showed surprisingly high drug encapsulation capacity compared to liposomes or other synthetic carriers. Furthermore, the sperm was capable to swim through complex environments in an efficient manner not only due to their tail beating but also due to their membrane biochemistry. A set of enzymes is expressed by sperms to catalyze the degradation of hyaluronic acid, which contributes to the constitution of the extracellular matrix of oocyte-surrounding cumulus cells. 57 It was widely reported that hyaluronic acid also plays an important role in the proliferation and migration of tumor tissue. 58 Therefore the motility and the hyaluronidases wielded by sperm cells allow them to penetrate deep into a tumor spheroid for effective in situ drug administration. Besides, sperm cells can remain functional in the human body for a longer time in comparison to other foreign cells due to the ability to inhibit the immune response by displaying specific glycans on the membrane. 59 This reduces undesired immuneresponse and thus makes this system compatible to the host body. Such sperm-hybrid micromotors not only have potential application for gynecologic cancer treatment but also for treating other diseases in the female reproductive tract such as endometriosis, pelvic inflammatory diseases, among others. Such devices can be also engineered to carry genes, mRNA, imaging contrast agents, among other substances of interest for diverse biomedical applications. Furthermore, these self-propelled carriers are promising to avoid the dilution in body fluids and undesired accumulation of such cargo, in contrast to other conventional carriers, as the cargo is internalized by the sperm and protected by its membrane. This drug loading process does not seem to interfere with sperm motility due to the sperm cell's incomplete metabolism that avoids intracellular degradation of the drug. Although there are still some challenges to overcome before this system can be applied in in vivo environments (e.g. imaging, biodegradation of the synthetic part, multiple sperms carrying and delivery, and improved control of sperm release), sperm-hybrid systems may be envisioned to be applied in in situ cancer diagnosis and treatment in the near future.
EXPERIMENTAL PART
Microfluidic platform fabrication
Microfluidic channels were fabricated by soft lithography. Briefly, a silicon wafer was spin coated with the negative photoresist SU-8 (SÜSS Microtec) and patterned by maskless lithography (μPG 501 Maskless Aligner, Heidelberg Instruments). After that, a mixture of PDMS and curing agent (Dow Corning Corp.) was poured onto the obtained mold and cured at 75 °C for 2h. The channels were designed to be 200 µm deep and 3 cm long. Two reservoirs were punched out at the inlet and the outlet after peeling off the PDMS channel from the mold. Finally, to complete the channel fabrication, the PDMS channel and a cleaned glass substrate were physically bonded after being exposed to oxygen plasma for about 0.5 min. To condition the inner channel surface, channels were filled with Pluronic® F-127 solution (10 μg/mL in DI water) (Sigma-Aldrich, Germany) and incubated for 1 h at 37 °C.
Pluronic® F-127 has been previously used to repel sperm cells, making it suitable for minimizing unspecific adhesion between sperms, the channel, and micromotor surfaces. 1 Before performing an experiment, the resulting channels were always rinsed with sperm medium (SP-TALP, see Table S1 ) 3 times.
Tetrapod fabrication
Arrays of polymeric tetrapods were fabricated by 3D laser lithography (Photonic Professional GT, Nanoscribe GmbH). Briefly, dip-in laser lithography photoresist (IP-Dip, Nanoscribe
GmbH) was dropped onto cleaned quartz glass substrates (25x25 mm²) as the basis polymer material for laser writing. The negative-tone photoresist was then polymerized specifically at preprogrammed exposure positions by two-photon absorption (laser wavelength 780 nm). The design of the tetrapod arrays was programmed with DeScribe software (Nanoscribe GmbH).
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Preparation of drug-loaded sperm cells
Bovine sperm cells were recovered by thawing cryopreserved sperm straws rapidly in a water bath at 38 °C for 2 min, and washed with BoviPure 100 / BoviDilute (40%/ 80%). 4 After 5 min centrifugation at 300 g in soft mode, the sperms were resuspended in 1 mL SP-TALP for subsequent use. Sperm concentration was calculated by using a cell counting chamber. 1 mg/mL of FITC-BSA (Fluorescein isothiocyanate conjugated bovine serum albumin) (SigmaAldrich, Germany) and DOX-HCl (doxorubicin hydrochloride) (Sigma-Aldrich, Germany) solution were prepared in SP-TALP, respectively, and stored under dark conditions at 4 °C.
To prepare drug-loaded sperm cells, a mixture of sperm solution and FITC-BSA or DOX-HCl solution at specific concentrations were co-incubated in a humidified atmosphere of 5% CO2
in air at 37 °C for 1 h. After washing the sample 2 times with SP-TALP by centrifugation at 300 g for 5 min, the pellet of drug-loaded sperms was redispersed in SP-TALP and stored in the incubator under dark conditions for subsequent use. It is important to note that the samples were to be used within 6 h to guarantee sperm motility.
HeLa cell spheroid preparation
HeLa cells were cultured in a 25 mL adherent flask for 2 weeks after recovering (for details of the medium see Table S2 ). To prepare tumor spheroids, the cells were first incubated in 2 mL Trypsin/EDTA for 10 min to be detached from the substrate. After dilution in 8 mL medium, the cell suspension was then centrifuged at 1000 rpm for 3.5 min to remove the medium. Then the cell pellet was resuspended in 1 mL medium. After calculation, 3×10 5 cells were suspended into 3 mL of medium and seeded in a spheroid-culture dish (Cellstar® CellRepellent Surface, Greiner bio-one). 5 After 3 days maturation, the spheroid solution was transferred into a 15 mL falcon and incubated for 5 min to separate the sediment cells.
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Finally, the bottom pellet of the spheroids was resuspended in 3 mL of new medium in the spheroid-culture dish for subsequent experiments.
Evaluation of sperm transport procedure
PDMS-based microfluidic chips were employed to evaluate the sperm-tetrapod coupling procedure, the magnetic guidance of the hybrid micromotors, and the sperm release by the mechanical trigger function. The chip featured a 500 µm wide channel where the spermtetrapod coupling and guidance occurred, and obstacles in 3 different shapes where the sperm release occurred (see Video S4). Tetrapods, PDMS channels and sperms were prepared and treated as mentioned before. After that, an array of tetrapods (1296 devices in total) was detached from the substrate by mechanical scratching and dispersed into 50 µL of SP-TALP. After coupling, the sperm-hybrid micromotor was guided by simply rotating a permanent magnet and the resulting directional changes were recorded to evaluate the guidance performance. The operating distance between the magnet and the sample was about 10 cm, resulting in an effective magnetic field of roughly 5 mT. Sperm release was evaluated by guiding the coupled motor onto different obstacles.
Evaluation of the drug loading procedure
The success of the drug loading procedure was evaluated by the determination of the Figure S6 shows the microfluidic chip that was designed for drug delivery experiments. The chip was designed to have a wide dosing region (where sperms are coupled to the tetrapods), a treatment region (where the tumor spheroid is located) and a constricted neck region in the middle to prevent the entry of non-coupled sperms into the treatment region. Drug-loaded sperms were prepared as mentioned earlier and observed under a fluorescence microscope using an excitation light with a wavelength of 470 nm (see Video S5, exposure time: 800 ms).
Evaluation of drug-loaded sperm delivery toward tumor spheroids
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After chip treatment with Pluronic® F-127 and SP-TALP, HeLa cell medium was first filled into the chip as the experimental environment. Then the HeLa spheroid was introduced into the chip from the left end and then 5 µL of tetrapod suspension (around 300) and 5 µL of drug-loaded sperms solution (3×10 5 /mL) were introduced from the right end. Real time videos of the transport process were recorded under the aforementioned microscope. With the guidance by an external magnet at a distance of ca. 10 cm, sperm-hybrid micromotors were guided to the target spheroid and the coupled drug-loaded sperms were released into the spheroid. Afterwards, the whole system was incubated in appropriate cell culture conditions (5% CO2 in air at 37 °C). At fixed time points, z-stack images of the sperm embedded spheroids were captured under the aforementioned fluorescence microscope. The exposure time of the fluorescent channel for all images was fixed at 800 ms. Subsequent semiquantitative analysis of the multi-channel images was executed with ImageJ. Figure S1 . Schematic depicting tumor targeted drug delivery by a sperm-hybrid micromotor under magnetic guidance with mechanical sperm release trigger. 
